While eczema is a common skin condition, it can manifest in many different ways. And with so much possible variation, it's not always easy to properly identify eczema. Eczema symptoms can be mild — a ...
If you experience chronic dry, itchy and red skin, you may be one of the millions of Americans with eczema. The National Eczema Association reports that an estimated 10% of the world population ...
Please provide your email address to receive an email when new articles are posted on . Tapinarof cream 1% showed low discontinuation rates. The cream has no restriction of use. Tapinarof patients ...
A small study recently found that the experimental drug nemolizumab (Mitchga) substantially improved itching in people with atopic dermatitis (AD). These improvements, in turn, were associated with ...
Reviewed By Steven R. Feldman, MD, PhD, Professor of Dermatology, Pathology and Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina Coping with the symptoms ...
Please provide your email address to receive an email when new articles are posted on . Eight of 10 participants reported an itch reduction score of 4 points by week 8. All participants reported a ...
- VTAMA® (tapinarof) cream, 1% demonstrated early, significant, and meaningful achievement of both no-to-minimal itch (mean weekly PP-NRS≤1) and sleep improvement in ADORING 1 and ADORING 2. - 31.4% ...
STAMFORD, Conn., March 28, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of ...
NEMLUVIO is the first authorized monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling ...
Post-hoc analyses of the phase III ARCADIA and OLYMPIA clinical trial programs, published in the Journal of the European Academy of Dermatology and Venereology, highlight nemolizumab's fast onset of ...
Nummular eczema is a debilitating skin condition that is distinct from atopic dermatitis but involves similar disease mechanisms including IL-13 and therefore makes targeting IL-13 with lebrikizumab a ...
Post-hoc analyses of the phase III ARCADIA and OLYMPIA clinical trial programs, published in the Journal of the European Academy of Dermatology and Venereology, highlight nemolizumab’s fast onset of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback